Jaguar Health files S-3 to register up to $75M in securities; plans NDA for crofelemer in MVID in mid-2027

Jaguar Health filed an SEC Form S-3 registration statement to register up to $75 million of securities to fund development activities and potential future offerings. Based on trial results, the company plans to submit a New Drug Application for crofelemer in the treatment of MVID in mid-2027.

Detected & updated continuously · Source: Nebula